Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
International Journal of Hematology|June 28, 2023
Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring systemHaruya Okamoto, Yu Inoue, Akihiro Miyashita, et al.
Leukemia & Lymphoma|July 19, 2019
Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphomaJunko Yamaguchi, Yoshiaki Chinen, Tomoko Takimoto-Shimomura, et al.
Cancer Medicine|February 24, 2018
Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapyYoshimi Mizuno, Taku Tsukamoto, Eri Kawata, et al.
Leukemia & Lymphoma|August 28, 2020
Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphomaYoshiaki Chinen, Kazuna Tanba, Ryo Takagi, et al.
International Journal of Hematology|December 11, 2023
Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myelomaAkio Onishi, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, et al.
Annals of Hematology|November 27, 2019
Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myelomaReiko Isa, Nobuhiko Uoshima, Ryoichi Takahashi, et al.
Leukemia & Lymphoma|February 11, 2022
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myelomaAyako Muramatsu, Tsutomu Kobayashi, Yuka Kawaji-Kanayama, et al.
Cancer Reports (Hoboken, N.J.)|June 14, 2021
Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patientsYuka Kawaji-Kanayama, Tsutomu Kobayashi, Ayako Muramatsu, et al.
International Journal of Hematology|January 24, 2022
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational studyYuka Kawaji-Kanayama, Ayako Muramatsu, Nana Sasaki, et al.
Leukemia & Lymphoma|March 26, 2025
Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective studyTakahiro Fujino, Haruya Okamoto, Daichi Nishiyama, et al.
Pageof 8